Compare Boston Scientific Corporation (BSX) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs ProShares UltraPro QQQ ETF — how do they compare? Boston Scientific Corporation trades at $43.35 (market cap $66.37B), while ProShares UltraPro QQQ ETF trades at $73.6. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | TQQQ | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $108.14 | $87.22 |
52-Week Low | $42.63 | $37.89 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
TQQQ, a 3x leveraged ETF tracking the Nasdaq-100, trades at $72.64, down 5.7% in the last 24 hours amid a bearish technical signal. The fund lacks traditional financial ratios as it is not a company, and recent news highlights concerns over volatility amplification and hidden costs. Support is seen at $72, with resistance at $74.
Outlook is cautious due to leveraged structure magnifying losses in downturns; opportunities exist for tactical traders during tech rallies, but risks include daily rebalancing decay and market volatility. Long-term holders face significant drawdown risks, as seen in 2022's 81% drop versus Nasdaq's 33% decline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
